NSE · SAIPARENT · Healthcare
Sai Parenteral's Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹57 Cr with net profit ₹10 Cr — a 17.52% net margin, versus 0.94% the period before.
Shareholding
As of 2026-06-30
- Promoter51.16%
- Public36.29%
- FII4.03%
- DII8.53%
9,312 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.77× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - General · ranked #1 of 1 by market cap
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sai Parenteral's Limited(this company) | ₹2,442 Cr | 137.48 | 4.97 | 2.91% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashSai Parenteral's Limited has a market capitalization of Rs 2509 Cr. The company reported revenue of Rs 163.74 Cr and an EPS of 3.23 for the latest period. The P/E ratio stands at 175.82, with a book value of 111.09. Return on equity (ROE) is 290.5%, and return on capital employed (ROCE) is 2.7874%.
Positives
- +The institutional shareholding increased from 0% in September 2025 to 12.5596% in June 2026.
- +The promoter pledge is 0%, indicating no shares are pledged by the promoters.
- +Annual revenue grew from Rs 97.028 Cr in Mar 2023 to Rs 163.744 Cr in Mar 2025.
Negatives
- −The profit margin is 0%, indicating no profit generation relative to revenue.
- −The debt-to-equity ratio is 1.26, suggesting a significant reliance on debt financing.
- −In Dec 2025, the company reported a negative net profit of -6.66 Cr and a negative EBITDA of -6.22.
- −The promoter holding decreased from 61.232% in September 2025 to 51.1553% in June 2026.
Financial performance
Sai Parenteral's Limited reported an annual revenue of Rs 163.744 Cr in Mar 2025, up from Rs 155.18 Cr in Mar 2024. Net profit for Mar 2025 was Rs 14.454 Cr, an increase from Rs 8.415 Cr in Mar 2024. The EPS for Mar 2025 was 5.43, compared to 10.54 in Mar 2024.
Profitability & returns
The company's return on equity (ROE) is 290.5%, and return on capital employed (ROCE) is 2.7874%. The profit margin is 0%. In the latest quarter ending Mar 2026, the net profit was Rs 13.16 Cr on a revenue of Rs 197.93 Cr.
Balance sheet
The debt-to-equity ratio for Sai Parenteral's Limited is 1.26. The book value per share is 111.09. The company has not declared a dividend, resulting in a dividend yield of 0%.
Ownership & pledges
Promoter holding stands at 51.1553% as of June 30, 2026. There are no pledged shares by the promoters.
Shareholding changes
Promoter holding decreased from 61.232% in Sep 2025 to 51.1553% in Mar 2026. Institutional holding increased from 0% in Sep 2025 to 12.5596% in June 2026. Public shareholding increased from 20.89% in Mar 2026 to 36.2851% in June 2026.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.